Skip to main content
. 2011 May 16;22(10):1209–1224. doi: 10.1089/hum.2010.215

FIG. 8.

FIG. 8.

T-cell expansion and activation of pp65-specific CD8+ T-cell responses in mice receiving different treatments: Monocytes expressing LV-pp65 (Mono LV-pp65), cDCs loaded with pp65 peptides (cDC pp65pp), cDCs expressing LV-pp65 (cDC LV-pp65), SMART-DCs, and SMART-DCs-pp65. Frequency of human CD3+/CD4+ T cells (a) and human CD3+/CD8+ T cells (b) in peripheral blood obtained from mice (n=3 per group) that were administered with APCs 7 days prior to T-cell infusion (left panel) or injected with APCs and T cells concurrently (right panel) and. Flow cytometry analyses were performed 10 days after T-cell infusion. (c) IFNγ-ELISPOT assay was performed with human CD3+ cells isolated from spleen 10 days after T-cell infusion. Averages of detectable spot counts (per 104 seeded cells) are shown. (d) Frequencies of T cells analyzed from peripheral blood and reactive against A*0201 restricted NLVPMVATV (diagonal-patterned bars) and B*0702 restricted TPRVTGGGAM (black) tetramers are shown. Percentages represent frequencies of tetramer positive/CD3+/CD8+ T cells. Error bars indicate standard deviation (SD) n=3 mice pre group *p<0.05.